RxDoctor Payments Data

Devi Pierce, MD

Internal Medicine · Corydon, INNPI 1144218496

Payments from drug & device makers

$553in general payments, 2019–2025

Across 29 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$74
  • AstraZeneca$71
  • Nevro Corp.$39
  • Lilly USA, LLC$36
  • AbbVie$35
  • Pacira Pharmaceuticals Incorporated$34
  • plus $264 from 11 others

What the payments were for

  • Food & beverage$52695%
  • Education$275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$553 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$75,205
Medicare patients
235
Services billed
857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin232$172,789
OzempicSemaglutide149$151,653
EliquisApixaban129$110,278
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$80,167
JanuviaSitagliptin Phosphate75$70,804
XareltoRivaroxaban62$57,079
Spiriva RespimatTiotropium Bromide66$43,708
LinzessLinaclotide50$36,437
MyrbetriqMirabegron55$31,604
Breo ElliptaFluticasone/Vilanterol62$31,324
FarxigaDapagliflozin Propanediol29$26,693
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$22,497
MounjaroTirzepatide15$21,444
CreonLipase/Protease/Amylase22$21,351
Tresiba Flextouch U-100Insulin Degludec28$20,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat$31$242,225338 claims
Novo NordiskOzempic$74$151,653149 claims
PfizerEliquis, Premarin$31$115,227145 claims
AbbVieLinzess, Creon$35$57,78872 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$71$57,32973 claims
Lilly USA, LLCMounjaro, Trulicity$36$34,90429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Corydon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →